8-K: Organogenesis Posts Record Q3 Revenue, Raises 2025 Guidance

Organogenesis Holdings Inc. reported record third-quarter 2025 financial results, driven by strong product revenue growth, and subsequently raised its full-year 2025 guidance.

Summary

• Net product revenue for the third quarter of 2025 was $150.5 million, an increase of 31% compared to $115.2 million for the third quarter of 2024.
• Advanced Wound Care product revenue increased by 31% to $141.5 million in Q3 2025, while Surgical & Sports Medicine product revenue increased by 25% to $9.0 million.
• Net income for Q3 2025 was $21.6 million, up from $12.3 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $30.1 million, a significant increase from $13.4 million in Q3 2024.
• For the nine months ended September 30, 2025, net product revenue decreased by 5% to $338.0 million compared to $355.4 million in the prior year period.
• The company reported a net loss of $6.7 million for the nine months ended September 30, 2025, compared to a net loss of $6.8 million for the same period in 2024.
• Adjusted EBITDA for the nine months ended September 30, 2025, was $14.0 million, a decrease from $31.6 million in the prior year period.
• Cash, cash equivalents, and restricted cash stood at $64.4 million as of September 30, 2025, down from $136.2 million at December 31, 2024.
• The company updated its fiscal year 2025 guidance, expecting net product revenue between $500.0 million and $525.0 million, representing a 4% to 9% year-over-year increase.
• Full-year 2025 net income is now projected between $8.6 million and $25.4 million, and Adjusted EBITDA between $45.5 million and $68.3 million.

Sentiment

Score: 8

Explanation: The company delivered strong third-quarter results with record revenue and significant increases in net income and Adjusted EBITDA, leading to raised full-year guidance. While year-to-date performance shows some declines and cash burn is notable, the positive Q3 momentum and optimistic outlook regarding CMS rules and new product potential (ReNu) indicate a strong positive sentiment.

Positives

• Record net product revenue of $150.5 million in Q3 2025, marking a 31% increase year-over-year.
• Significant increase in Q3 2025 net income to $21.6 million, up $9.2 million from Q3 2024.
• Substantial increase in Q3 2025 Adjusted EBITDA to $30.1 million, an increase of $16.7 million from Q3 2024.
• Raised full-year 2025 net product revenue guidance to a range of $500.0 million to $525.0 million, representing a 4% to 9% year-over-year increase.
• Raised full-year 2025 profitability guidance, with net income expected between $8.6 million and $25.4 million, and Adjusted EBITDA between $45.5 million and $68.3 million.
• Strong growth in both Advanced Wound Care (31% increase) and Surgical & Sports Medicine (25% increase) product revenues in Q3 2025.
• Gross profit margin for Q3 2025 remained strong at 76% of net product revenue.
• No outstanding debt obligations as of September 30, 2025.
• Management believes the company is well-positioned for 2026 and beyond, propelled by the strength of its evidence-based portfolio and the transformative potential of ReNu in a significant new market opportunity, especially in light of the recently announced CMS payment rule.

Negatives

• Net product revenue for the nine months ended September 30, 2025, decreased by 5% to $338.0 million compared to $355.4 million in the prior year period.
• Advanced Wound Care revenue for the nine months decreased by 6% ($21.0 million decrease).
• Operating loss for the nine months ended September 30, 2025, increased to $18.6 million from $11.5 million in the prior year period.
• Adjusted net income for the nine months decreased by $9.4 million to $2.3 million compared to $11.7 million in the prior year period.
• Adjusted EBITDA for the nine months decreased by $17.7 million to $14.0 million compared to $31.6 million in the prior year period.
• Cash, cash equivalents, and restricted cash decreased significantly from $136.2 million at December 31, 2024, to $64.4 million at September 30, 2025.
• Impairment and write-down expenses of $0.9 million were recorded in Q3 2025, and $9.2 million for the nine months ended September 30, 2025, related to an asset held for sale.
• A restructuring charge of $0.5 million was incurred for the nine months ended September 30, 2025, related to employee severance and other exit costs.

Risks

• The impact and uncertainty of any changes to the coverage and reimbursement levels for the company's products, including potential effects from proposed LCDs and finalized CMS rules related to skin substitute products that could take effect as soon as January 1, 2026.
• Significant and continuing competition in the markets the company operates in, which could adversely affect its business, results of operations, and financial condition.
• Rapid technological change could cause the company's products to become obsolete if product offerings are not enhanced through research and development efforts.
• The necessity to convince physicians that the company's products are safe and effective alternatives to existing treatments and should be used in their procedures for commercial success.
• The company's ability to raise funds to expand its business.
• The company has incurred losses in the current and prior periods and may incur losses in the future.
• Changes in applicable laws or regulations.
• The possibility that the company may be adversely affected by other economic, business, and/or competitive factors.
• The company's ability to maintain production or obtain supply of its products in sufficient quantities to meet demand.
• Any resurgence of the COVID-19 pandemic or the occurrence of another public health emergency and its potential impact on the company's fiscal condition and results of operations.
• The impact of the suspension of commercialization of ReNu and NuCel in connection with the expiration of the FDA's enforcement grace period for HCT/Ps on May 31, 2021.
• The impact of the suspension of Dermagraft in the second quarter of 2022 pending transition of manufacturing to a new facility or a third-party manufacturer.
• Uncertainty regarding whether the company is able to obtain regulatory approval for and successfully commercialize ReNu.
• Other risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the company's Form 10-K for the year ended December 31, 2024, and its subsequently filed periodic reports.

Future Outlook

The company updated its fiscal year 2025 guidance, expecting net product revenue between $500.0 million and $525.0 million, representing a 4% to 9% year-over-year increase. Net income is projected to be between $8.6 million and $25.4 million, and Adjusted EBITDA between $45.5 million and $68.3 million. Management anticipates being well-positioned in 2026 and beyond, driven by the strength of its evidence-based portfolio and the potential of ReNu in a significant new and addressable market opportunity, especially in light of the recently announced CMS payment rule.

Management Comments

• "Our record revenue performance in the third quarter reflects the team's strong execution and commitment to our strategy, leveraging our deep customer relationships to promote access to new and existing products despite the continued challenging environment." Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis.
• "In light of the recently announced CMS payment rule, I believe we are well-positioned in 2026 and beyond propelled by the strength of our evidence-based portfolio of regenerative technologies combined with the transformative potential of ReNu in a significant new and addressable market opportunity." Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis.

Industry Context

The announcement highlights the impact of the "recently announced CMS payment rule" and the "transformative potential of ReNu in a significant new and addressable market opportunity." This suggests that changes in healthcare reimbursement policies and the introduction of new regenerative technologies like ReNu are key drivers and potential disruptors in the Advanced Wound Care and Surgical & Sports Medicine markets. The company positions itself to benefit from these changes in 2026 and beyond, indicating a strategic focus on adapting to regulatory shifts and capitalizing on product innovation within the regenerative medicine sector.

Related Party Transactions

• Operating lease obligations with related parties are disclosed on the balance sheet, with a current portion of $3.798 million and a non-current portion of $5.419 million as of September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact due to strong Q3 performance, raised guidance, and potential for future growth from new products and a favorable regulatory environment.
• Employees: Positive impact from strong company performance and strategic execution, though restructuring charges were mentioned in non-GAAP adjustments for the nine months.
• Customers: Continued access to new and existing Advanced Wound Care and Surgical & Sports Medicine products.
• Creditors: Positive due to no outstanding debt obligations.

Next Steps

• Management will host a conference call on November 6, 2025, at 5:00 p.m. Eastern Time to discuss the results of the quarter and provide a corporate update with a question and answer session.
• The company aims to obtain regulatory approval for and successfully commercialize ReNu.
• Transition Dermagraft manufacturing to a new facility or a third-party manufacturer.
• Continue leveraging deep customer relationships and strategic execution to promote access to new and existing products.

Key Dates

Recommendation

Organogenesis reported a robust third quarter with record revenue and substantial increases in profitability metrics, leading to an upward revision of its full-year 2025 guidance. The company's strategic positioning, particularly with the CMS payment rule and the potential of ReNu, suggests strong future growth prospects. Despite some year-to-date declines and cash usage, the strong Q3 momentum, absence of debt, and positive management outlook make it an attractive investment.

Keywords

Regenerative Medicine, Advanced Wound Care, Surgical & Sports Medicine, Biotechnology, Medical Devices, SEC Filing, Financial Results, Revenue Guidance, EBITDA, Net Income, Organogenesis, ORGO, CMS Payment Rule, ReNu, Dermagraft, NuCel